Actos (Pioglitazone) Cost in Montana 2026: Prices, Insurance, and Savings

What Does Pioglitazone Actually Cost in Montana?

Generic pioglitazone is one of the least expensive branded-to-generic conversions in endocrinology. The average cash price across Montana retail pharmacies sits at about $15 per month for a 30-day supply of 30 mg or 45 mg tablets, based on 2026 pharmacy aggregator data. Brand-name Actos from Takeda carries a list price near $60 per month, but almost no one fills the brand anymore.

Price variation between pharmacies matters. A Walmart or Costco pharmacy in Billings or Missoula may dispense a 90-day generic supply for under $12 total through their in-house discount programs. Independent pharmacies in more rural parts of the state, including communities in eastern Montana, sometimes price a 30-day fill between $18 and $25 without a discount card. Using a GoodRx or RxSaver coupon at checkout typically brings the price back to the $10 to $15 range at any chain pharmacy.

Pioglitazone belongs to the thiazolidinedione (TZD) class. The FDA-approved prescribing information lists type 2 diabetes mellitus as its indicated use, either as monotherapy or combined with metformin, sulfonylureas, or insulin. Off-label prescribing for nonalcoholic steatohepatitis (NASH) is supported by the PIVENS trial, a landmark RCT published in the New England Journal of Medicine in 2010 (N=247) that demonstrated histological improvement in 34% of pioglitazone-treated patients versus 19% on placebo (P=0.04) [1][2].

The cost picture in Montana is favorable compared to many diabetes medications. A month of brand-name semaglutide (Ozempic) runs over $900 without insurance, while a month of pioglitazone costs less than a coffee subscription.

Montana Medicaid and Pioglitazone: What You Need to Know

Montana Medicaid does not currently cover pioglitazone. This applies to both brand-name Actos and generic formulations. The state's preferred drug list (PDL) for diabetes instead prioritizes metformin, sulfonylureas, and select DPP-4 inhibitors as first-line oral agents.

Patients enrolled in Montana Medicaid who need pioglitazone have a few options. A prescriber can submit a prior authorization request demonstrating medical necessity, such as metformin intolerance (GI side effects affect roughly 20 to 25% of patients per ADA Standards of Care) or a co-existing NASH diagnosis [3]. Approval rates for these requests vary and the process can take 5 to 10 business days.

The alternative is paying cash. At $15 per month, pioglitazone is cheap enough that many Medicaid-enrolled patients choose to pay out of pocket rather than manage the prior authorization process. Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has noted: "Cost should never be the reason a patient doesn't get the medication they need for diabetes management" [3].

For patients also receiving care through the Indian Health Service (IHS), which serves several tribal communities across Montana, pioglitazone is typically available at no cost through IHS formularies. The Billings Area IHS covers seven reservations in Montana, and TZDs remain on most facility formularies.

Insurance Coverage Across Montana Plans

Most commercial insurance plans available in Montana place generic pioglitazone on Tier 1 (preferred generic), carrying a copay between $0 and $15. This applies to major carriers operating in the state, including Blue Cross Blue Shield of Montana, Pacific Source, and plans offered through the federal marketplace at HealthCare.gov.

Employer-sponsored plans through large Montana employers like Billings Clinic, Benefis Health System, and the state government generally cover pioglitazone without prior authorization. The Endocrine Society's clinical practice guidelines recognize pioglitazone as an effective second-line agent for type 2 diabetes, which supports formulary inclusion [4].

Medicare Part D plans in Montana show wide variation. Most standard plans cover generic pioglitazone with a $0 to $10 copay during the initial coverage phase. Under the Inflation Reduction Act provisions that took full effect in 2025, Medicare beneficiaries benefit from the $2,000 annual out-of-pocket cap on Part D spending. For a medication costing $15 per month ($180 per year), pioglitazone alone won't approach that cap, but it counts toward total diabetes medication spending for patients on multiple drugs.

A key detail: if your plan covers pioglitazone but requires a step-through (try metformin first), your prescriber needs to document the clinical rationale for skipping or stopping metformin. Common documented reasons include eGFR below 30 mL/min/1.73 m², lactic acidosis risk, or confirmed GI intolerance despite extended-release formulation.

Compounded Pioglitazone in Montana

Compounded pioglitazone is legal and available in Montana through licensed 503A pharmacies. These are pharmacies that compound medications based on individual patient prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act. Montana's Board of Pharmacy permits 503A compounding provided the pharmacy holds a valid state license and follows USP 795 standards for nonsterile preparations [5].

Why would someone compound a drug that already costs $15 in generic form? Two practical reasons exist. First, some patients need a dose not commercially available (for example, 7.5 mg for NASH, which is being studied in lower-dose protocols). Second, patients who cannot swallow tablets may need a liquid suspension.

Montana has approximately 15 to 20 503A-licensed compounding pharmacies, concentrated in Billings, Great Falls, Missoula, and Helena. Compounded pioglitazone pricing varies, but some pharmacies offer it at minimal cost, particularly for simple tablet reformulations. Patients should confirm that the compounding pharmacy sources pioglitazone active pharmaceutical ingredient (API) from an FDA-registered supplier.

The FDA's guidance on compounding specifies that 503A pharmacies may not compound drugs that are essentially copies of commercially available products unless a prescriber documents a clinical difference for the specific patient. This means a prescriber must write the prescription with a documented reason the commercial product won't work [5].

Telehealth Prescribing for Pioglitazone in Montana

Montana permits telehealth prescribing of pioglitazone without restriction. The state's telehealth parity law requires insurers to cover telehealth visits at the same rate as in-person visits, and pioglitazone is not a controlled substance, so no DEA-related telehealth limitations apply.

This matters significantly for rural Montana. The state spans 147,040 square miles with a population of roughly 1.1 million people. Counties like Garfield, Petroleum, and Carter have fewer than 2,000 residents and no endocrinologist within 100 miles. Telehealth allows patients in these areas to receive a pioglitazone prescription from a board-certified provider without a multi-hour drive.

HealthRX and similar telehealth platforms can prescribe pioglitazone to Montana residents after a virtual consultation. The prescriber reviews labs (fasting glucose, HbA1c, liver function tests, and a baseline echocardiogram if heart failure risk factors are present), assesses contraindications, and sends the prescription to the patient's preferred Montana pharmacy. Lab monitoring typically includes liver function tests at baseline and periodically thereafter, per FDA labeling [2].

One clinical guardrail: pioglitazone is contraindicated in patients with NYHA Class III or IV heart failure. The PROactive trial (N=5,238) demonstrated a modest increase in heart failure hospitalizations (11% vs. 8%, P=0.007) despite an overall reduction in the composite cardiovascular endpoint [6]. Telehealth prescribers must screen for this before writing the prescription.

Discount Programs and Savings Cards

Several pathways exist to reduce pioglitazone costs in Montana below the already-low $15 average.

GoodRx, RxSaver, and similar aggregators. These free platforms negotiate pharmacy benefit manager (PBM) rates and display them as coupons. In May 2026, GoodRx shows generic pioglitazone 30 mg (30 tablets) priced between $8 and $14 at Montana pharmacies including Walgreens, Albertsons, and Smith's.

Walmart $4 program. Walmart's ReliOn and discount prescription lists have historically included pioglitazone at $4 for a 30-day supply (30 mg) and $10 for 90 days. Montana has Walmart pharmacies in Billings, Bozeman, Butte, Great Falls, Helena, Kalispell, and Missoula.

Manufacturer savings. Takeda's branded Actos savings card is largely irrelevant for Montana patients since the generic is cheaper than any branded copay card benefit. Generic manufacturers (Teva, Mylan, and others) do not typically offer direct-to-consumer savings programs for pioglitazone because the price point is already at commodity level.

340B pricing. Federally qualified health centers (FQHCs) and eligible hospitals in Montana can dispense pioglitazone at 340B pricing, which is often pennies per tablet. Montana has over 50 FQHC sites, including Community Health Partners in Livingston and Bozeman, Bullhook Community Health Center in Havre, and RiverStone Health in Billings. Patients receiving care at these facilities may pay $0 to $5 for a month's supply.

Patient assistance programs. NeedyMeds and RxAssist maintain databases of patient assistance options. For a $15-per-month generic, formal patient assistance programs are rarely necessary, but they exist for patients with no income and no insurance who need documentation for Medicaid appeals [7].

Pioglitazone for NASH: Montana Access Considerations

Off-label pioglitazone prescribing for NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) is growing nationally, and Montana is no exception. The PIVENS trial showed that pioglitazone 30 mg daily produced resolution of NASH in 47% of treated patients compared to 21% on placebo over 96 weeks [1].

The AASLD practice guidance on NAFLD states: "Pioglitazone can be used to treat biopsy-proven NASH in patients with and without type 2 diabetes" [8]. Dr. Arun Sanyal, a hepatologist at Virginia Commonwealth University who led the PIVENS trial, has described pioglitazone as "the most cost-effective pharmacotherapy we have for NASH today, at a fraction of the cost of emerging therapies" [1].

For Montana patients, this off-label use creates an insurance wrinkle. Even when pioglitazone is covered for diabetes, insurers may deny coverage when the diagnosis code is K75.81 (NASH) rather than E11.x (type 2 diabetes). Prescribers can work around this by listing the diabetes diagnosis as the primary indication if the patient carries both diagnoses. For patients with NASH but without diabetes, cash-pay at $15 per month remains the simplest path.

Montana has limited hepatology specialty access. The state has fewer than 10 practicing hepatologists, mostly in Billings and Missoula. Telehealth access to out-of-state hepatologists who can prescribe pioglitazone for NASH is an increasingly common pathway for rural Montana patients with biopsy-confirmed disease.

How Pioglitazone Pricing Compares to Other Diabetes Drugs in Montana

Putting pioglitazone's $15-per-month cost in context helps patients and prescribers make informed formulary decisions.

Metformin runs $4 to $8 per month in Montana. That's cheaper, and metformin remains the standard first-line agent per ADA Standards of Care 2026 [3]. Pioglitazone's cost advantage shows up when compared to newer drug classes. Empagliflozin (Jardiance) costs $550 to $600 per month at list price. Semaglutide tablets (Rybelsus) list above $900 per month. Even generic glipizide, at $4 to $10 per month, sits in a similar price bracket to pioglitazone but carries hypoglycemia risk that pioglitazone does not.

The PROactive study (N=5,238) demonstrated a 16% relative reduction in the secondary composite endpoint of all-cause mortality, nonfatal MI, and stroke with pioglitazone versus placebo over a mean follow-up of 34.5 months [6]. This cardiovascular benefit, combined with the NASH signal from PIVENS, makes pioglitazone a remarkably cost-effective drug for the right patient profile: someone with type 2 diabetes, evidence of hepatic steatosis, and no heart failure.

Patients taking pioglitazone should expect weight gain of 2 to 4 kg on average. The drug promotes fluid retention and adipocyte differentiation. Peripheral edema occurs in approximately 5% of patients on monotherapy, rising to 15% when combined with insulin per the FDA prescribing label [2]. Bone density monitoring is recommended for postmenopausal women, as TZDs are associated with increased fracture risk at distal extremities.